Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China

Approximately 40% to 50% of gastrointestinal stromal tumor (GIST) patients will have recurrence or metastases after resection of the primary lesion, and the most common affected sites will be liver and peritoneum. Imatinib has been considered as the first-line therapy of metastatic GIST. Surgery for...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yi-Nan, Li, Yong, Wang, Li-Ping, Wang, Zhen-Hua, Liang, Xiao-Bo, Liang, Han, Zhang, Li, Li, Bin, Fan, Li-Qiao, Zhao, Qun, Ma, Zhi-Xue, Zhao, Xue-Feng, Zhang, Zhi-Dong, Liu, Yu, Tan, Bi-Bo, Wang, Dong, Wang, Li-Li, Hao, Ying-Jie, Jia, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
3700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704785/
https://www.ncbi.nlm.nih.gov/pubmed/29145240
http://dx.doi.org/10.1097/MD.0000000000008240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704785/
https://www.ncbi.nlm.nih.gov/pubmed/29145240
http://dx.doi.org/10.1097/MD.0000000000008240

Ejemplares similares